Fig. 4: Prognostic impact of ineffective erythropoiesis (assessed by ARC) in MDS patients. | Blood Cancer Journal

Fig. 4: Prognostic impact of ineffective erythropoiesis (assessed by ARC) in MDS patients.

From: Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre

Fig. 4

a–c Survival analyses of ARC in the total cohort, IPSS-R lower-risk patients and IPSS-R higher-risk patients, respectively. d Survival analyses of MDS patients stratified by IPSS-R risk group and ARC. e, f Survival analyses of ARC in younger (<60 years) and older (≥60 years) patients. g–i Survival analyses of ARC in IPSS-R lower-risk patients who received immunosupressive treatment and IPSS-R higher-risk patients who received decitabine therapy or in both categories who received Allo-HSCT.

Back to article page